Pamela L. Kunz
Key Documents
Contact Information
-
Clinical Offices
Oncology 875 Blake Wilbur Dr MC 5826 Stanford, CA 94305 Tel Work (650) 725-9057 Fax (650) 498-5353
- Academic Offices
Alternate Contact Gail Samaroo Administrative Associate Email Tel Work 650-725-9057Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer
- Esophageal Cancer
- Gastrointestinal Cancers
- Neuroendocrine
- Oncology (Cancer)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2010) |
| Board Certification: | Oncology, ABIM (2010) |
| Fellowship: | Stanford Hospital and Clinics CA (2007) |
| Residency: | Stanford Hospital and Clinics CA (2005) |
| Residency: | SUMC - Graduate Medical Education CA (2004) |
Scientific Focus
Current Research Interests
I specialize in the treatment of gastrointestinal malignancies. My research involves clinical trials and epidemiologic studies, primarily in neuroendocrine and gastroesophageal cancers.
Clinical Trials
- Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer Recruiting
- Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Recruiting
- Phase III Depot Octreotide + Interferon Alpha vs Depot Octreotide+ Bevacizumab in Advanced Carcinoid Recruiting
- Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct Recruiting
Publications
- HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012; (1): 13-24
- 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010; (5): 1420-5
- Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol. 2010: 79-86
- Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010; (16): 3943-52
- Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer. 2010; (22): 5179-87
Help